Remdesivir as a possible therapeutic option for the COVID-19.
作者信息
Al-Tawfiq Jaffar A, Al-Homoud Ali H, Memish Ziad A
机构信息
Infectious Disease Unit, Specialty Internal Medicine and Infection Control Unit, Quality and Patient Safety, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pharmacy Services Division, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
出版信息
Travel Med Infect Dis. 2020 Mar-Apr;34:101615. doi: 10.1016/j.tmaid.2020.101615. Epub 2020 Mar 5.
Abstract
摘要
相似文献
1
Remdesivir as a possible therapeutic option for the COVID-19.瑞德西韦作为治疗新冠肺炎的一种可能选择。
Travel Med Infect Dis. 2020 Mar-Apr;34:101615. doi: 10.1016/j.tmaid.2020.101615. Epub 2020 Mar 5.
2
Rapid review for the anti-coronavirus effect of remdesivir.瑞德西韦抗冠状病毒作用的快速综述。
Drug Discov Ther. 2020;14(2):73-76. doi: 10.5582/ddt.2020.01015.
3
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
4
[Remdesivir for patients with COVID-19].[瑞德西韦用于新型冠状病毒肺炎患者]
Internist (Berl). 2020 Aug;61(8):869-872. doi: 10.1007/s00108-020-00836-7.
5
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
6
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?我们用瑞德西韦（一种老药新包装）找到了治疗新冠病毒肺炎的万灵药了吗？
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
7
Efficacy of Remdesivir in COVID-19.瑞德西韦治疗新型冠状病毒肺炎的疗效
JAMA. 2020 Sep 15;324(11):1041-1042. doi: 10.1001/jama.2020.16337.
8
Pulmonary administration of remdesivir in the treatment of COVID-19.瑞德西韦肺部给药治疗新型冠状病毒肺炎
AAPS J. 2020 Sep 17;22(6):121. doi: 10.1208/s12248-020-00506-4.
9
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
10
Remdesivir for the Treatment of Covid-19 - Preliminary Report.瑞德西韦治疗新型冠状病毒肺炎——初步报告
N Engl J Med. 2020 Sep 3;383(10):993-994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
引用本文的文献
1
Primary Pyrrolimines and Pyridinimines.伯吡咯啉和吡啶亚胺。
Molecules. 2025 Mar 10;30(6):1239. doi: 10.3390/molecules30061239.
2
Unlocking the potential of approach in designing antibodies against SARS-CoV-2.挖掘该方法在设计抗SARS-CoV-2抗体方面的潜力。
Front Bioinform. 2025 Feb 13;5:1533983. doi: 10.3389/fbinf.2025.1533983. eCollection 2025.
3
Study of Hydrolysis Kinetics and Synthesis of Single Isomer of Phosphoramidate ProTide-Acyclovir.磷酰胺前药阿昔洛韦单异构体的水解动力学研究及合成
ACS Omega. 2024 Nov 1;9(45):45221-45231. doi: 10.1021/acsomega.4c06645. eCollection 2024 Nov 12.
4
Harnessing immunity: Immunomodulatory therapies in COVID-19.利用免疫：COVID-19中的免疫调节疗法。
World J Virol. 2024 Jun 25;13(2):92521. doi: 10.5501/wjv.v13.i2.92521.
5
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
6
Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.治疗管理的再利用方法：COVID-19 爆发期间的一个谜。
Curr Mol Med. 2024;24(6):712-733. doi: 10.2174/1566524023666230613141746.
7
Increased expression and its association with altered purine metabolism in cell lines derived from different stages of colorectal cancer.在源自不同阶段结直肠癌的细胞系中表达增加及其与嘌呤代谢改变的关联。
Exp Ther Med. 2023 Mar 24;25(5):212. doi: 10.3892/etm.2023.11911. eCollection 2023 May.
8
Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives.铂-核苷（t）化合物作为抗肿瘤/抗病毒治疗的潜在抗代谢物：性质与前景
Pharmaceutics. 2023 Mar 14;15(3):941. doi: 10.3390/pharmaceutics15030941.
9
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines.2019冠状病毒病最新情况：严重急性呼吸综合征冠状病毒2变种、抗病毒药物及疫苗
Heliyon. 2023 Mar;9(3):e13952. doi: 10.1016/j.heliyon.2023.e13952. Epub 2023 Feb 23.
10
Potential Inhibitors of SARS-CoV-2 Main Protease (M) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies.通过分子对接研究从美国食品药品监督管理局（FDA）批准的药物库中鉴定出的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要蛋白酶（M）的潜在抑制剂。
Biomedicines. 2022 Dec 29;11(1):85. doi: 10.3390/biomedicines11010085.
本文引用的文献
1
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.从过去中学习：针对 2019-nCoV 引起的严重急性呼吸道感染的可能紧急预防和治疗选择。
Chembiochem. 2020 Mar 2;21(5):730-738. doi: 10.1002/cbic.202000047. Epub 2020 Feb 25.
2
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
3
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.比较瑞德西韦与洛匹那韦利托那韦和干扰素β联合治疗中东呼吸综合征冠状病毒的疗效。
Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.
4
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
5
MERS-CoV as an emerging respiratory illness: A review of prevention methods.中东呼吸综合征冠状病毒作为一种新发呼吸道疾病：预防方法综述
Travel Med Infect Dis. 2019 Nov-Dec;32:101520. doi: 10.1016/j.tmaid.2019.101520. Epub 2019 Nov 12.
6
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.冠状病毒对抗病毒药物瑞德西韦（GS-5734）的易感性是由病毒聚合酶和校对核糖核酸外切酶介导的。
mBio. 2018 Mar 6;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
7
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.广谱抗病毒药物GS-5734可抑制流行性冠状病毒和人畜共患冠状病毒。
Sci Transl Med. 2017 Jun 28;9(396). doi: 10.1126/scitranslmed.aal3653.
8
Late Ebola virus relapse causing meningoencephalitis: a case report.晚期埃博拉病毒复发致脑膜脑炎：一例报告
Lancet. 2016 Jul 30;388(10043):498-503. doi: 10.1016/S0140-6736(16)30386-5. Epub 2016 May 18.
9
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.小分子GS-5734对恒河猴体内埃博拉病毒的治疗效果。
Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2.
Zotero 插件